Product Pipeline
Making consortia therapeutics possible
Through its unique CORAL® platform for disease-focused therapeutic consortia design, optimization and manufacturing, MRM Health develops effective live bacterial consortia therapeutics with an excellent safety profile and disease-modifying potential. The Company’s unique manufacturing technology allows to produce bacterial consortia as a single Drug Substance, resulting in a highly cost-effective and scalable manufacturing route. The diverse pipeline of MRM Health includes therapeutic programs for inflammatory bowel diseases, CNS disorders, metabolic diseases and auto-immune diseases.
Clinical programs
Ongoing Phase 2 with MH002 in Ulcerative Colitis and the orphan indication Pouchitis.
Preclinical programs
Parkinson’s disease.
Metabolic diseases (partnered).
Discovery programs
Ongoing program in spondylarthritis and autoimmune conditions.
Effective live biotherapeutics
Designed for efficacy, developed for synergy, produced as one.
Contact us